Logo

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

Share this

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

Shots:

  • The BT Designation is based on the P-II CHRONOS-1 study which involves assessing of 25 patients with relapsed or refractory MZL who have received at least two prior therapies
  • The study resulted in ORR of overall iNHL population (n=142) was 59.2%- while the MZL patients (23%)- @18 mos. ORR (60.6% and 78.3%) in FAS population and MZL histology
  • Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Additionally- Bayer is conducting two P-III studies CHRONOS-3 and CHRONOS-4 evaluating the safety and efficacy of Aliqopa

Click here ­ to­ read full press release/ article | Ref: Bayer | Image: Bayer


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions